The renowned La Jolla science factory Scripps Research Institute changed its name in August to Scripps Research. Now it’s adding a layer of leadership.
The nonprofit institute has established a 21-member Board of Overseers, which will “include influencers in biotechnology, pharmaceuticals, academia, law, science policy and investment,” it was announced Wednesday.
Pete Schultz, president and CEO of Scripps Research, says the new board will serve in an “advisory capacity to institute leadership and its Board of Directors regarding academic, scientific and business strategies, as well as provide support for the institute’s philanthropic efforts.”Members, including six women, will not be paid, said a spokeswoman.
Their primary role isn’t to raise money.
“It’s to provide guidance and connections,” said Madeline McCurry-Schmidt, community liaison. “They can help connect us with supporters and those who want to get involved or work here.”
The new board’s main purpose is to provide guidance to senior leadership of the institute and expertise from their own perspectives in leadership positions, she said.
“These are people who have expressed to us their excitement and support for the work we are doing at Scripps Research and want to collaborate with us from an advisory capacity,” McCurry-Schmidt told Times of San Diego.
Members were announced at the institute’s Board of Directors meeting Sept. 28.
Among the overseers is Rajiv Kaul, a portfolio manager and research analyst for Fidelity Investments, who manages Fidelity’s Select Biotechnology Portfolio and its Fidelity Advisor Biotechnology Fund.
“We’re in a golden age of innovation and medicine,” he says, “with newly discovered strategies for addressing more and more of the diseases that affect the human population. Pete [Schultz] has both the scientific understanding and business expertise to accelerate delivery of these new medicines from Scripps Research and Calibr to the patient.”
Another is Magda Marquet, co-founder and co-CEO of ALMA Life Sciences LLC, an investment and consulting firm with a portfolio of 20 private investments.
She says her three decades of experience in the biotechnology industry in both the United States and Europe will be readily shared with Scripps Research.
“Let’s not forget that … San Diego is a thriving cluster for life sciences,” she says.
Overseer Joe Panetta, president and CEO of Biocom, which advocates for the life sciences industry in California, said: “Scripps Research has been responsible, directly and indirectly, for the development of many cutting-edge therapies, as well as the training of top scientists. It has contributed significantly to the overall global reputation of San Diego as a leading life sciences cluster.”
In recent years, Scripps Research has been broadening its scope from fundamental scientific research into drug discovery and development, as well as the utilization of genomics and digital tools to promote individualized medicine.
Other women on the new board are:
- Jacqueline K. Barton, Chair, Division of Chemistry and Chemical Engineering, Kirkwood Noyes Professor of Chemistry, California Institute of Technology.
- Karen Bernstein, co-founder and chairman, BioCentury.
- Marjorie Fink, supporter and community volunteer, Scripps Research, Florida.
- Tina S. Nova, president and CEO, Molecular Stethoscope Inc.
- And Lynn A. Schenk, attorney at law and former member of Congress.
>> Subscribe to Times of San Diego’s free daily email newsletter! Click hereFollow Us: